Search results

Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

2 September 2020

Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

30 September 2020

Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

25 February 2015

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

9 August 2017

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

Result type

Technology appraisal guidance

Published

22 February 2017

Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

24 January 2018

Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

21 March 2018

In development [GID-TA11186] Expected publication date: TBC

Result type

Technology appraisal guidance

Status

In development

In development [GID-TA11587] Expected publication date: 25 June 2025

Result type

Technology appraisal guidance

Status

In development

Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

10 April 2024

Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

Discontinued [GID-TAG526]

Result type

Technology appraisal guidance

Status

Discontinued

TA333 Renal cell carcinoma, locally advanced and/or metastatic (2nd line) - axitinib [ID518] 10 June 2013 TA219 Renal cell carcinoma...

treatments. Source guidance details Comes from guidance Axitinib for treating advanced renal cell carcinoma after failure of prior...

Result type

Research recommendation

Published

9 June 2015